Drug Trial Radar · NCT06149494
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Nov 20, 2023
Primary completion
Mar 30, 2025
Study completion Mar 30, 2025
Sponsor
- Lead sponsor
- Altesa Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Virtus Respiratory Research
- First posted
- Nov 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.
Conditions
- COPD Exacerbation Acute
- COPD With Acute Lower Respiratory Infection
- Rhinovirus
- Virus Diseases
- Virus Infection, RNA
- Enterovirus
- Enterovirus Infections
- Rhinovirus Infection
- Infection Viral
- Respiratory Complication
- Respiratory Disease
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiratory Viral Infection
- Upper Resp Tract Infection
- Upper Respiratory Tract Infections
- Upper Respiratory Disease
- Upper Respiratory Disorder
- Upper Respiratory Disease, Acute
- Upper Respiratory Infection Viral
- Infections, Respiratory
- Infections
- Copd
- Viral Infection
- Emphysema or COPD
- Lower Respiratory Disease
- Lower Respiratory Disorder
- Lower Respiratory Tract and Lung Infections
- Pulmonary Disease
- Pulmonary Disease, Chronic Obstructive
- Respiratory Disease Chronic
- Lung Diseases
- Lung Disease Chronic
- Obstructive Pulmonary Disease
- Chronic Lower Respiratory Diseases
- Chronic Respiratory Disease
Interventions
VapendavirDrug
Participants randomized to the experimental cohort will be administered Vapendavir.
PlaceboDrug
Participants randomized to the placebo cohort will be administered placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak change from baselineTime frame: From Baseline Visit through Follow-Up Visit, up to 7 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.